Nalaganje...
Population pharmacokinetics of siltuximab: Impact of disease state
PURPOSE: To characterize the effects of disease type and clinical characteristics on the pharmacokinetics of siltuximab, an IL-6 inhibiting monoclonal antibody. METHODS: Siltuximab pharmacokinetic data were combined from 7 phase I/II clinical trials. A population pharmacokinetic model was developed...
Shranjeno v:
| izdano v: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800650/ https://ncbi.nlm.nih.gov/pubmed/31482226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03939-7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|